Company Update

Securities and Exchange Commission (SEC) ( https://www.sec.gov/Archives/edgar/data/27367/000149315223018750/form497.htm#Ha_006 ). The offering documents cited next generation technology development specifically as one of the uses of proceeds from the offering.   The Company announces that it specifically reserved $550,000 of the proceeds from the May 22, 2023 public offering to support the development of a proprietary hematocrit capability compatible with its next generation technologies.   The company anticipates that development work will proceed over a 12 month period and will be in conjunction with other technology development efforts supported by the Department of Defense for the Company’s next generation technologies.     2       SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.     DAXOR CORPORATION   (Registrant)     Date: October 27, 2023 By: /s/ Robert J. Michel   Name: Robert J. Michel   Title: Chief Financial Officer     3       About Daxor Corporation   Daxor Corporation (Nasdaq: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at Daxor.com .   Forward-Looking Statements   Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.   Investor Relations Contact:   Bret Shapiro Sr. Managing Partner,CORE IR 516-222-2560 brets@coreir.com       4